A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Clinical trial NCT03439293 · COMPLETED
Trial details
- NCT number
- NCT03439293
- Sponsor
- Takeda
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-13
- Primary completion
- 2022-01-01
- Enrollment
- 61
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.